Your browser doesn't support javascript.
loading
Mice humanized for MHC and hACE2 with high permissiveness to SARS-CoV-2 omicron replication.
Le Chevalier, Fabien; Authié, Pierre; Chardenoux, Sébastien; Bourgine, Maryline; Vesin, Benjamin; Cussigh, Delphine; Sassier, Yohann; Fert, Ingrid; Noirat, Amandine; Nemirov, Kirill; Anna, François; Bérard, Marion; Guinet, Françoise; Hardy, David; Charneau, Pierre; Lemonnier, François; Langa-Vives, Francina; Majlessi, Laleh.
Afiliação
  • Le Chevalier F; Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Virology Department, 75724 Paris, France. Electronic address: fabien.le-chevalier@pasteur.fr.
  • Authié P; Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Virology Department, 75724 Paris, France. Electronic address: pauthie@theravectys.com.
  • Chardenoux S; Mouse Genetics Engineering, Institut Pasteur, Université Paris Cité, 75724 Paris, France. Electronic address: sebastien.chardenoux@pasteur.fr.
  • Bourgine M; Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Virology Department, 75724 Paris, France. Electronic address: maryline.bourgine@pasteur.fr.
  • Vesin B; Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Virology Department, 75724 Paris, France. Electronic address: benjamin.vesin@pasteur.fr.
  • Cussigh D; Mouse Genetics Engineering, Institut Pasteur, Université Paris Cité, 75724 Paris, France. Electronic address: delphine.cussigh@pasteur.fr.
  • Sassier Y; Mouse Genetics Engineering, Institut Pasteur, Université Paris Cité, 75724 Paris, France. Electronic address: yohann.sassier@pasteur.fr.
  • Fert I; Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Virology Department, 75724 Paris, France. Electronic address: ifert@theravectys.com.
  • Noirat A; Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Virology Department, 75724 Paris, France. Electronic address: anoirat@theravectys.com.
  • Nemirov K; Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Virology Department, 75724 Paris, France. Electronic address: knemirov@theravectys.com.
  • Anna F; Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Virology Department, 75724 Paris, France. Electronic address: francois.anna@pasteur.fr.
  • Bérard M; Institut Pasteur, Université Paris Cité, DT, Animalerie Centrale, 75724 Paris, France. Electronic address: marion.berard@pasteur.fr.
  • Guinet F; Lymphocytes and Immunity Unit, Institut Pasteur, Université Paris Cité, Immunology Department, 75724 Paris, France. Electronic address: francoise.guinet@pasteur.fr.
  • Hardy D; Histopathology Platform, Institut Pasteur, Université Paris Cité, 75724 Paris, France. Electronic address: david.hardy@pasteur.fr.
  • Charneau P; Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Virology Department, 75724 Paris, France. Electronic address: pierre.charneau@pasteur.fr.
  • Lemonnier F; Unit, Institut Cochin - INSERM U1016 - CNRS UMR8104 - Paris F-75014, France. Electronic address: francois.lemonnier@inserm.fr.
  • Langa-Vives F; Mouse Genetics Engineering, Institut Pasteur, Université Paris Cité, 75724 Paris, France. Electronic address: francina.langa-vives@pasteur.fr.
  • Majlessi L; Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Virology Department, 75724 Paris, France. Electronic address: laleh.majlessi@pasteur.fr.
Microbes Infect ; 25(7): 105142, 2023.
Article em En | MEDLINE | ID: mdl-37080384
ABSTRACT
Human Angiotensin-Converting Enzyme 2 (hACE2) is the major receptor enabling host cell invasion by SARS-CoV-2 via interaction with Spike. The murine ACE2 does not interact efficiently with SARS-CoV-2 Spike and therefore the laboratory mouse strains are not permissive to SARS-CoV-2 replication. Here, we generated new hACE2 transgenic mice, which harbor the hACE2 gene under the human keratin 18 promoter, in "HHD-DR1" background. HHD-DR1 mice are fully devoid of murine Major Histocompatibility Complex (MHC) molecules of class-I and -II and express only MHC molecules from Human Leukocyte Antigen (HLA) HLA 02.01, DRA01.01, DRB1.01.01 alleles, widely expressed in human populations. We selected three transgenic strains, with various hACE2 mRNA expression levels and distinctive profiles of lung and/or brain permissiveness to SARS-CoV-2 replication. These new hACE2 transgenic strains display high permissiveness to the replication of SARS-CoV-2 Omicron sub-variants, while the previously available B6.K18-ACE22Prlmn/JAX mice have been reported to be poorly susceptible to infection with Omicron. As a first application, one of these MHC- and ACE2-humanized strains was successfully used to show the efficacy of a lentiviral-based COVID-19 vaccine.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enzima de Conversão de Angiotensina 2 / COVID-19 Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enzima de Conversão de Angiotensina 2 / COVID-19 Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article